• Explore /
  • Poster
  • / Phase III study of first-line pembrolizumab (pembro) plus lenvatinib (len) in patients (pts) with advanced urothelial carcinoma (UC) ineligible for platinum-based chemotherapy: LEAP-011.

Phase III study of first-line pembrolizumab (pembro) plus lenvatinib (len) in patients (pts) with advanced urothelial carcinoma (UC) ineligible for platinum-based chemotherapy: LEAP-011.

Abstract Poster

Authors

Yohann Loriot

Yohann Loriot

Gustave Roussy, Villejuif, France

Yohann Loriot , Arjun Vasant Balar , Ronald De Wit , Jorge A. Garcia , Petros Grivas , Nobuaki Matsubara , Blanca Homet Moreno , Eric Sbar , Xieyang Calvin Jia , Corina E. Dutcus , Arlene O. Siefker-Radtke

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers

Track

Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03898180

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr TPS597)

Abstract #

TPS597

Poster Bd #

N15

Abstract Disclosures

Similar Posters

First Author: Arlene O. Siefker-Radtke

First Author: Lillian L. Siu

First Author: Nataliya Mar

First Author: Dean F. Bajorin